Cure Rare Disease (CRD) - a Boston-based 501c3 nonprofit biotech - announces the approval from the U.S. Food and Drug Administration (FDA) to administer its very first therapeutic. The drug, named CRD-TMH-001, treats muscle promoter and exon 1 mutations on the dystrophin gene. With the IND approval process complete, the FDA has given the go-ahead, and dosing of the drug will occur imminently at the University of Massachusetts Medical School. Hear from CRD founder & CEO Rich Horgan on this monumental success.
Learn more: [ Ссылка ]
Donate: [ Ссылка ]
Contact us:
@CureRareDisease on Facebook, Instagram, Twitter and LinkedIn
info@curerd.org
media@cureRD.org
